Literature DB >> 25540736

Diagnosis and management of coronary allograft vasculopathy in children and adolescents.

Nathalie Dedieu1, Gerald Greil1, James Wong1, Matthew Fenton1, Michael Burch1, Tarique Hussain1.   

Abstract

Coronary allograft vasculopathy remains one of the leading causes of death beyond the first year post transplant. As a result of denervation following transplantation, patients lack ischaemic symptoms and presentation is often late when the graft is already compromised. Current diagnostic tools are rather invasive, or in case of angiography, significantly lack sensitivity. Therefore a non-invasive tool that could allow early diagnosis would be invaluable.This paper review the disease form its different diagnosis techniques,including new and less invasive diagnostic tools to its pharmacological management and possible treatments.

Entities:  

Keywords:  Allograft vasculopathy; Cardiac transplantation; Diagnosis; Management which reflect the content of the study; Paediatrics

Year:  2014        PMID: 25540736      PMCID: PMC4274597          DOI: 10.5500/wjt.v4.i4.276

Source DB:  PubMed          Journal:  World J Transplant        ISSN: 2220-3230


  169 in total

1.  Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging.

Authors:  S R Kapadia; K M Ziada; P L L'Allier; T D Crowe; G Rincon; R E Hobbs; C Bott-Silverman; J B Young; S E Nissen; E M Tuzcu
Journal:  J Heart Lung Transplant       Date:  2000-02       Impact factor: 10.247

2.  Coronary flow reserve by transthoracic echocardiography predicts epicardial intimal thickening in cardiac allograft vasculopathy.

Authors:  F Tona; E Osto; G Tarantini; A Gambino; F Cavallin; G Feltrin; R Montisci; A L P Caforio; G Gerosa; S Iliceto
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

3.  Prevalence of different gadolinium enhancement patterns in patients after heart transplantation.

Authors:  Henning Steen; Constanze Merten; Sonja Refle; Roland Klingenberg; Thomas Dengler; Evangelos Giannitsis; Hugo A Katus
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

4.  Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

Authors:  J A Kobashigawa; L W Miller; S D Russell; G A Ewald; M J Zucker; L R Goldberg; H J Eisen; K Salm; D Tolzman; J Gao; W Fitzsimmons; R First
Journal:  Am J Transplant       Date:  2006-06       Impact factor: 8.086

5.  The results of cardiac retransplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry.

Authors:  R Srivastava; B M Keck; L E Bennett; J D Hosenpud
Journal:  Transplantation       Date:  2000-08-27       Impact factor: 4.939

6.  Myocardial perfusion scintigraphy as a screening method for significant coronary artery stenosis in cardiac transplant recipients.

Authors:  J Carlsen; J C Toft; S A Mortensen; H Arendrup; J Aldershvile; B Hesse
Journal:  J Heart Lung Transplant       Date:  2000-09       Impact factor: 10.247

7.  Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

Authors:  Howard J Eisen; Jon Kobashigawa; Anne Keogh; Robert Bourge; Dale Renlund; Robert Mentzer; Edwin Alderman; Hannah Valantine; Georges Dureau; Donna Mancini; Richard Mamelok; Robert Gordon; Whedy Wang; Mandeep Mehra; Maria Rosa Constanzo; Manfred Hummel; Jay Johnson
Journal:  J Heart Lung Transplant       Date:  2005-05       Impact factor: 10.247

8.  Intravascular ultrasound correlates with coronary flow reserve and predicts the survival in angiographically normal cardiac transplant recipients.

Authors:  Chii-Ming Lee; Yen-Wen Wu; Hsiang-Yiang Jui; Ruoh-Fang Yen; Kai-Yuan Tzen; Nai-Kuan Chou; Shoei-Shen Wang
Journal:  Cardiology       Date:  2007-08-03       Impact factor: 1.869

9.  Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure.

Authors:  Jan Groetzner; Ingo Kaczmarek; Bruno Meiser; Markus Müller; Sabine Daebritz; Bruno Reichart
Journal:  J Heart Lung Transplant       Date:  2004-06       Impact factor: 10.247

10.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.